Logo

Celltrion Reports Submission of MAA to EMA for CT-P17 (biosimilar- adalimumab)

Share this

Celltrion Reports Submission of MAA to EMA for CT-P17 (biosimilar- adalimumab)

Shots:

  • Celltrion has applied for the commercial approval of CT-P17- a biosimilar referencing Humira (adalimumab) in the EU
  • The submission is based on clinical data targeting all approved indications of Humira- including RA- UC- and psoriasis and is expected to be available in the EU market in about a year. Additionally- Celltrion is conducting P-III clinical studies of CT-P16 (biosimilar- bevacizumab) referencing Genentech’s Avastin for multiple cancer indications
  • CT-P17 is the first high-concentration adalimumab biosimilar and is different from the existing biosimilars of Humira in terms of dosing. The drug is citrate free that means it will cause less pain upon injection

Click here ­to­ read full press release/ article 

 Ref: Korean Herald | Image: Celltrion


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions